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Background: Agonistic CD40 antibodies have been demonstrated to activate antigen-presenting cells (APCs) and
enhance antitumour T cell responses, thereby providing a new therapeutic option in cancer immunotherapy.
In agonistic CD40 antibody-mediated inflammatory responses, a novel subset of E-cadherin + dendritic cells
(DCs) has been identified, and little is known about the role of these DCs in tumour immunity. This study
investigated the effect of anti-CD40-mediated inflammatory E-cadherin + DCs in murine Lewis lung carcinoma (LLC).
Methods: The phenotype and characteristics of anti-CD40-mediated inflammatory E-cadherin + DCs isolated from the
anti-CD40 model were assessed in vitro. The antitumour activity of E-cadherin + DCs were evaluated in vivo by
promoting the differentiation of effector CD4+ T cells, CEA-specific CD8+ T cells and CD103+ CD8+ T cells
and assessing their resistance to tumour challenge, including variations in tumour volume and survival curves.
Results: Here, we demonstrated that anti-CD40-mediated E-cadherin + inflammatory DCs accumulate in the
lungs of Rag1 KO mice and were able to stimulate naïve CD4+ T cells to induce Th1 and Th17 cell differentiation
and polarisation and to inhibit regulatory T cell and Th2 responses. Importantly, with the adoptive transfer of
E-cadherin + DCs into the Lewis lung cancer model, the inflammatory DCs increased the Th1 and Th17 cell
responses and reduced the Treg cell and Th2 responses. Interestingly, following the injection of inflammatory
E-cadherin + DCs, the CD103+ CD8+ T cell and CEA-specific CD8+ T cell responses increased and exhibited
potent antitumour immunity.
Conclusions: These findings indicate that anti-CD40-induced E-cadherin + DCs enhance T cell responses and
antitumour activity in non-small cell lung cancer (NSCLC)-bearing mice and may be used to enhance the efficacy
of DC-based peptide vaccines against NSCLC.
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CD40 is a tumour necrosis factor receptor superfamily
member that is expressed on antigen-presenting cells
(APCs) such as dendritic cells (DC), B cells, monocytes
and some tumour cells. Recently, agonistic CD40 anti-
bodies were applied in clinical trials targeting advanced
pancreatic ductal adenocarcinoma (CP-870,893) and diffuse
large B cell lymphoma (dacetuzumab and Chi Lob 7/4).
The CD40 agonistic antibody has displayed excellent anti-
tumour activity in the patients in these trials [1,2]. Many
subsets of DCs exist in the agonistic CD40 antibody-
mediated tumour microenvironment or under sterile in-
flammatory response conditions. However, the mechanism
and function of CD40-mediated inflammatory DCs in
cancer immunity are unknown.
In CD40 agonistic antibody-mediated inflammatory
responses, a novel subset of E-cadherin + DCs has been
identified. Although CD40 signalling is critical for the dif-
ferentiation of inflammatory monocytes into E-cadherin +
inflammatory DCs and the promotion of anti-CD40-
mediated colitis has been confirmed in Rag1 KO mice
[3], little is known regarding the role of E-cadherin +
inflammatory DCs in tumour immunity.
Precisely how inflammatory DCs with tumour antigen
peptides can induce a T cell response in tumour immun-
ity is poorly understood. Here, we identified the inflam-
matory E-cadherin + DCs that accumulate in the lung
during the anti-CD40 antibody-mediated inflammatory
response. The phenotypes of these DCs are the same as
those of spleen-derived inflammatory E-cadherin + DCs
that are present during anti-CD40-mediated colitis. The
agonistic CD40 mAb has not been universally accepted
as a novel cancer therapy. Concerns include cytokine
release syndromes, autoimmune reactions [4], thrombo-
embolic syndromes, hyperimmune stimulation leading to
activation-induced cell apoptosis or tolerance [5,6] and
tumour angiogenesis, possibly as a result of the CD40-
dependent activation of tumour endothelial cells [7].
These effects may cause unacceptable toxicity or promote
tumour growth [8]. This study aimed to investigate the
effects of anti-CD40-induced E-cadherin + DCs on the
T cell response and antitumour activity in the tumour
microenvironment. We found that inflammatory E-
cadherin + DCs were present only in anti-CD40-mediated
innate immunity, not innate, adoptive and tumour
immunity. Our study will address the disadvantages
of agonistic CD40 mAb in tumour therapy and may
provide novel therapeutic strategies, as well as ex-
plain the pathogenesis of non-small cell lung cancer
(NSCLC).
Materials and methods
Additional materials and methods can be found in the
Additional file 1.Animals
We obtained 6- to 8-week-old C57BL/6 mice from the
Wuhan University Centre for Animal Experiments.
B6.129S7-Rag1tmiMom/JNju (Rag1−/−) mice (background:
C57BL/6) were provided by the Mode Animal Research
Centre of Nanjing University. These Rag1−/− mice were
housed and maintained in individual ventilated cages
(IVC) under specific pathogen-free conditions; C57BL/6
mice were housed in specific pathogen-free conditions but
not under IVC conditions. All breeding was conducted in
the Huazhong University of Science and Technology
Centre for Animal Experiments according to the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals.
Cell isolation
Spleens were digested with collagenase VIII (Sigma) as
previously described [9] and filtered using a 70-μm cell
strainer (BD Biosciences) to obtain mononuclear spleen
cells. Lung or lung tumour tissues were cut into pieces,
and mononuclear cells were digested with collagenase V
(Sigma) for 2 h at 37°C as described previously [10]. The
resulting spleen or lung cell suspensions from anti-CD40
model mice were stained using E-cadherin, CD11c, CD4,
CD103 and 7-AAD. The cells were first sorted for 7-
AAD−CD11c+ cells using a FACS AriaIII sorter (BD
Biosciences); 7-AAD + CD11c- cells were discarded. The
CD11c + cells were then sorted into E-cadherin + and
E-cadherin- DCs (E-cadherin+/− CD11chigh CD4-CD103-
7-AAD-, purity >98%), as described (Additional file 1:
Figure S1). The DC subsets were cultured in DMEM
(GIBCO, Invitrogen) supplemented with 10% foetal bo-
vine serum (FBS, GIBCO, Invitrogen), LPS (1 μg/ml),
streptomycin (100 μg/ml) and penicillin (100 U/ml) [3].
Naive CD4+ T cells (CD4 + CD62L + CD44low) and
naive CD8+ T cells (CD8 + CD62L + CD44low) were pre-
pared from cell suspensions isolated from the spleens of
6-8-week-old C57BL/6 mice. The cells were isolated
using a FACSAriaIII sorter. The cells were first sorted
for CD4+ T cells, which were then sorted for CD62L +
CD44low cells. Similarly, CD8 + CD62L + CD44low cells
were sorted from the CD8+ T cells, and naive CD8+ T
cells were obtained. The naive T cell (CD4+/CD8+ T)
purities exceeded 99% (Additional file 1: Figure S2).
T cell differentiation and polarisation assay
Cell suspensions were prepared from the spleens of the
anti-CD40 model of Rag1−/− or C57BL/6 mice. Briefly,
3.2 × 104 E-cadherin + or E-cadherin- CD11chighCD4-
CD103-7-AAD-cells (E-cadherin + or E-cadherin- DCs,
respectively) were cultured with or without 5 μg/ml
CEA421-435 peptide (Invitrogen) for 24 h; 3.5 × 105
sorted naive CD4+ T cells were then added to the E-
cadherin + or E-cadherin- DCs in complete RPMI 1640
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R&D Systems), plate-bound anti-CD3 and soluble anti-
CD28 (5 μg/ml each, eBioscience) [11], either under Th1,
Th2 and Th17 conditions for 96 h or Treg conditions for 5
days. Then, the Th1, Th2 and Th17 cells and the relevant
cytokines were analysed at 72 h and 96 h. Treg cells and
the relevant cytokines were analysed at 72 h and on day 5.
Cell supernatants were collected and stored at −80°C for
subsequent analysis of CD4+ T cell differentiation using
the mouse Th1/Th2/Th17/Th22 13-plex kit (eBioscience)
and the mouse TGF-β1 simplex kit (eBioscience). For Th1,
Th2 and Th17 effector T cell polarisation analysis, multi-
plying system cells were collected on day 3 and analysed
with the mouse Th1/Th2/Th17 phenotyping kit (BD
Biosciences); for the Treg cell analysis, the mouse Th17/
Treg phenotyping kit (BD Biosciences) was used after
multiplying system cells collected at day 5.
For CD8+ T cell differentiation analysis, 2.3 × 104 E-
cadherin + or E-cadherin- DCs that were cultured with
5 μg/ml CEA526-533 peptide (Invitrogen) for 24 h were
cultured with 3 × 105 sorted naive CD8+ T cells, anti-CD3
(1 μg/ml) and anti-CD28 (5 μg/ml). The naive CD8 +
Tcells cultured with anti-CD3 (1 μg/ml) and anti-CD28
(5 μg/ml) (no DCs) were considered as a control. At 48 h,
the supernatant was collected to detect IFN-γ secretion
using the mouse IFN-γ ELISA Kit (R&D systems).
In vivo experiments
For the in vivo experiments, 5 × 105 E-cadherin +
CD11chighCD103−CD4-7AAD- DCs from the spleens of
the Rag1−/− anti-CD40 mouse model were transferred
into the orthotopic or subcutaneous lung tumour model
by tail vein injection at day 7, day 14 or day 21 after the
tumour model was established (the day of tumour cell
injection was day 0). The same number of E-cadherin-
CD11chighCD103-CD4-7AAD- DCs and 200 μl of PBS
were injected as controls. The E-cadherin + and E-
cadherin- CD11chigh cell fractions were cultured with 5
μg/ml CEA526-533 peptide (Invitrogen) for 24 h prior
to i.v. injection into the LLC tumour-bearing mice. At
day 28, the orthotopic lung tumour-bearing mice were
sacrificed, and the tumour tissues were harvested and
prepared to investigate the effects of the E-cadherin +
DCs on the helper T cell response using PCR and western
blotting analyses. Lung tissue from orthotopic tumour-
bearing mice was also prepared as a cell suspension to
assay CD103 expression in CD8+ T cells. Spleen lympho-
cytes of orthotopic tumour-bearing mice were stained for
tetramer staining.
Statistical analyses
All data are expressed as the mean ± SD. Significant re-
sults were assessed using analysis of variance. Statistical
significance between alues was determined using Student’st test, and a statistically significant difference between two
test groups was defined as P < 0.05.
Results
The phenotype of inflammatory E-cadherin + DCs in the
lung
A subset of E-cadherin + inflammatory DCs has been
identified in an anti-CD40 colitis model [3]. However,
the presence of these CD40-mediated E-cadherin + DCs
in the lung and their phenotype are unknown. To inves-
tigate the expression of E-cadherin in lung dendritic
cells in the presence of different immune responses, we
harvested lung tissue from the Lewis orthotopic lung
cancer model, C57BL/6, Rag1 KO mice and Rag1 KO
mice exposed to an anti-CD40 antibody, respectively.
Interestingly, the fluorescence levels of E-cadherin and
CD11c in the lung tumour were low, with E-cadherin
only expressed in a minor fraction of the lung tissue of
C57BL/6 mice, whereas the expression of E-cadherin
and CD11c in the lung tissue of Rag1 KO mice exposed
to an anti-CD40 antibody was increased and significantly
greater than their expression in the Lewis orthotopic
lung cancer model and C57BL/6 mice (Figure 1A). We
then analysed whether E-cadherin was expressed in lung
DCs undergoing a CD40 mAb-mediated inflammatory
response. We showed that a minor subset of CD11chigh
cells expressed E-cadherin in the lung, and approximately
11.3% of CD11chigh cells expressed E-cadherin during the
CD40 mAb-mediated inflammatory response. The major-
ity of lung-derived E-cadherin + and E-cadherin- DCs
expressed high levels of CD11b and CD103 while express-
ing CD4 at low levels. The majority of E-cadherin + DCs
expressed CD103 under steady-state conditions [3],
whereas the phenotype of E-cadherin + DCs in the lung
under anti-CD40 conditions was the same as that of
E-cadherin + DCs in the spleen (E-cadherin +
CD11chighCD11bhighCD103-CD4-) (Figure 1B). These
findings suggest that the phenotype of lung inflammatory
E-cadherin + DCs mimics that of E-cadherin + DCs in the
spleen [3] with regard to CD40 mAb-mediated inflamma-
tory responses.
The effects of E-cadherin + DCs on effector T cells
(Th1 and Th2)
Inflammatory E-cadherin + BM-DCs isolated from the
CD4 + CD45RBhigh T cell colitis model promote the Th17
response, whereas the Th1 response is not significantly al-
tered from that in response to E-cadherin- BM-DCs [3].
To investigate the effects of CD40-mediated E-cadherin +
DCs isolated from the spleens of anti-CD40 Rag1 KO
mice on the Th1 and Th2 responses in the tumour micro-
environment, naive CD4+ T cells were incubated for 96 h
with E-cadherin + DCs or E-cadherin- DCs, both of
which had been pre-incubated with 5 μg/ml CEA421-435
Figure 1 E-cadherin expression on lung dendritic cell in terms of lung tumour immunity, adoptive immunity (C57BL6), innate
immunity (Rag1 KO) and CD40-mediated immune response (CD40/Rag1 ko). (A) Lung tissues were harvested from the Lewis lung
cancer model, C57/BL6 mice, Rag1 KO mice and the anti-CD40 model, respectively. The green fluorescence represents CD11c, and red represents
E-cadherin. (B) The phenotype of inflammatory E-cadherin + DCs in lung and spleen cell suspensions. The spleen and lung cells were harvested
from the anti-CD40 model. For the lung cell test, E-cadherin and CD11c expression was analysed in sorted CD11chigh cells prepared from a lung
single-cell suspension (sorted using a BD FACSAria III flow cytometer). Staining for CD11b, CD4, CD103 and E-cadherin and were gated on
E-cadherin+/−CD11chigh cells from lung cells. For the spleen cell test, E-cadherin and CD11c expression was examined in a spleen single-cell
suspension. Staining for CD4, CD103 and E-cadherin gated on E-cadherin+/−CD11chigh cells to analyse the expression of CD103 and CD4. Each
experiment was performed in triplicate.
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increased the number of IFN-γ + CD4+ T cells and de-
creased the number of IL-4 + CD4+ T cells (Figure 2A),
whereas extracellularly, IFN-γ and IL-2 secretion was
greater than that of the E-cadherin- DC group. However,
the secretion of IL-4, IL-5 and IL-13 decreased when com-
pared with that of E-cadherin- DCs. Interestingly, in the
E-cadherin + DCs, the secretion of IL-6 was significantly
greater than that in the E-cadherin- DCs (Figure 2B).
These data suggest that CD40-mediated inflammatory E-
cadherin +DCs are able to promote the Th1 response and
inhibit the Th2 response in tumour immunity when carry-
ing the CEA peptide.
E-cadherin + DCs promote the Th17 response and
decrease the percentage of Treg cells
The differentiation of Th17 cells was enhanced by E-
cadherin + DCs in vivo. However, no differences were
observed in the frequency of Treg cells compared with
E-cadherin- BM-DCs [3]. In light of these findings, we ex-
amined the effects of the CD40-mediated E-cadherin +
DCs on Th17 and Treg cells. The sorted naive CD4+ T
cells were incubated with the CEA421-435 peptide. We
showed that the addition of E-cadherin + DCs led to aprofound upregulation of Th17 polarisation and reduced
the polarisation of Treg cells. Changes in the same func-
tions of Th17 cells and Treg cells were weak in the E-
cadherin- DC controls (Figure 3A). We then analysed the
secretion of IL-17, IL-10 and TGF-β in the presence or ab-
sence of anti-CD40 spleen-derived E-cadherin + DCs. Re-
garding the secretion of Th17 and Treg cell cytokines, a
similar difference was observed between the E-cadherin +
DCs and E-cadherin- DCs. Following the addition of E-
cadherin +DCs, the secretion of IL-17 was greater than
that of the E-cadherin- DC controls; nevertheless, the
secretion of IL-10 and TGF-β was decreased compared
with the E-cadherin- DCs (Figure 3B). We concluded that
CD40-mediated E-cadherin DCs are potent inducers of
Th17 cell-mediated responses and suppressors of Treg cell
differentiation when carrying the CEA peptide in vitro.
E-cadherin + DCs enhance the T cell response in
orthotopic Lewis lung cancer model
We have shown that CD40-mediated inflammatory E-
cadherin + DCs enhance T cell responses in tumour im-
munity in vitro. However, T cell responses are typically
inhibited in tumour immunity, especially in effector CD4+
T cells (Th1, Th2 and Th17 responses). Inflammatory DCs
Figure 2 Relationship between inflammatory E-cadherin + DCs and Th1 and Th2 cells. (A) The polarisation of Th1 cells with the percentage
of CD4 + IFN-γ + T cells and the polarisation of Th2 cells with percentage of CD4 + IL-4+ T cells. Percentage of IFN-γ + CD4+ cells and IL-4 + CD4+
cells from the E-cadherin + DCs and E-cadherin- DCs groups, according to the gating of CD4+ T cells. (B) Secretion of cytokines from Th1 and
Th2 cells. Cytokine secretion was measured in the supernatant using the FlowCytomix kit (eBioscience). The supernatant was harvested at 72 h
and 96 h and then analysed for Th1 (IFN-γ) and Th2 (IL-4, IL-5, IL-6, IL-13). Each experiment was performed in triplicate. The asterisk indicates a
significant difference between the two test groups, as analysed by Student’s t-test. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
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the effect of inflammatory E-cadherin + DCs on the T cell
response and antitumour activity in vivo, we transferred
5 × 105 E-cadherin +DCs loaded with the CEA526-533
peptide into an orthotopic lung tumour model by tail-vein
injection on days 7, 14, and 21 following tumour establish-
ment. On day 28, five of the tumour-bearing mice were
sacrificed, and the measured tumour volumes of those
mice injected with E-cadherin +DCs were reduced rela-
tive to mice that received E-cadherin- DCs or the PBS
control (Figure 4A-B). Interestingly, upon staining the tet-
ramers of PE-CEA526-533/H-2Db in the spleen lympho-
cytes of tumour-bearing mice, we found that the percentage
of CD8+ CEA526-533 tetramer + T cells was greater than
that in mice that received E-cadherin- DCs and the PBS
control mice (Figure 4C). We has observed the similar
variation of CD8+ CEA526-533 tetramer + T cells on
day14 and day 21 (Additional file 1: Figure S5). CD103 +
CD8+ T cells have been shown to have an effective role in
inhibiting breast cancer and glioma progression [12,13].
However, the effects of these DCs on lung CD103 + CD8+T cells are unknown. In the lung cells of tumour-bearing
mice injected with E-cadherin + DCs, we showed that
the percentage of CD8+ T cells expressing CD103 was
approximately 15.2%, whereas those of mice injected with
E-cadherin- DCs or PBS were approximately 3.7% and
0.51%, respectively (Figure 4C), suggesting that CD40-
mediated inflammatory E-cadherin + DCs enhance CEA-
specific, CD8+ T cell responses and the expression of
CD103 by CD8+ T cells in the lung tumour immune
microenvironment.
To investigate the effect of CD40-mediated E-cadherin +
DCs on CD4+ T lymphocytes of lung tumours, tumour
tissue was harvested for qRT-PCR and western blot-
ting. In this tumour immunity microenvironment model,
with E-cadherin + DC treatment carrying the CEA526-533
antigen peptide, the transcription of T-bet and RORγt was
enhanced compared with mice that received E-cadherin-
DCs and the PBS control mice, whereas FOXP3 tran-
scription was reduced (Figure 4D). The protein levels of
IFN-γ and IL-17 were increased in the E-cadherin + DC
group, whereas TGF-β was decreased. The transcription
Figure 3 The effects of inflammatory E-cadherin + DCs on Th17 and Treg cells. (A) The polarisation of Th17 cells with the percentage of
CD4 + IL-17+ T cells and polarisation of Treg cells with the percentage of CD4 + Foxp3+ T cells. Percentage of Foxp3 + CD4+ cells and IL-17 +
CD4+ cells from the E-cadherin + DCs and E-cadherin- DCs groups, according to the gating of CD4 + T cells. (B) Cytokine secretion was measured
in the supernatant using the FlowCytomix kit (eBioscience). The supernatant harvested at 72 h and 96 h was used to assess IL-17 secretion, and
the supernatant harvested at 72 h and on day 5 was used to assess IL-10 and TGF-β secretion. Each experiment was performed in triplicate. An
asterisk indicates a significant difference between the two test groups, as analysed by Student’s t-test (*P < 0.05, ***P < 0.001).
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the tumour tissue exposed to E-cadherin + DCs relative to
that exposed to E-cadherin- DCs (Figure 4D-E).
The effects of E-cadherin + DCs on antitumour activity in
Lewis lung cancer model
To further determine whether E-cadherin + DCs enhanced
the antitumour activity and prolonged the survival time of
tumour-bearing mice, we monitored tumour growth and
the survival time of the subcutaneous model, as well as
the survival time for the orthotopic lung tumour model
(Figure 5A-C). Following transfer of E-cadherin + DCs
loaded with the CEA526-533 peptide, the subcutaneous
tumour volume decreased significantly compared with the
E-cadherin- DC group. The E-cadherin +DCs prolonged
the survival time of the subcutaneous and orthotopic lung
tumour-bearing mice. However, no mice survived in the
PBS-vaccinated group.
Discussion
A subset of DCs not found in the steady state occurs as
a consequence of inflammation or antibody-mediated
sterile inflammation. These DCs have been termed inflam-
matory DCs. Inflammatory monocytes are the main pre-
cursors of inflammatory DCs [14]. These precursors, such
as Gr1 + CD115+ inflammatory monocytes, can differenti-
ate into E-cadherin + DCs through GM-CSF mediation
[3]. Although a few DCs express E-cadherin in normal
mice, the inflammatory E-cadherin + DCs detected in thelungs of the lung tumour model are not detected. Here,
we demonstrated that E-cadherin + DCs accumulated in
the lung and spleen during CD40 mAb-mediated innate
immunity, indicating that the provisions of the CD40 sig-
nalling pathway are sufficient to drive the accumulation of
inflammatory DCs expressing E-cadherin.
Monocyte-derived inflammatory DCs play an early
role in adaptive immunity [15]. However, these cells have
not been shown to prime naive T cells in vivo, and their
functions in tumour immunity in vitro and in vivo are
unknown. The differences in the activities of DC subsets
on naive T cells depend on the phenotype of the DCs.
CD8α + DCs could play a role in tolerance induction
and restrict the immune response, whereas CD8α- DCs
could be stimulatory to the T cell response [16]. CD40-
mediated inflammatory E-cadherin + DCs do not express
CD8α and CD4. Surprisingly, Pulendran et al. and
Maldonado-Lopez et al. demonstrated that CD8α + DCs
lead to Th1 differentiation and that CD8α- DCs induce
a Th2-type response [17,18]. Although E-cadherin + and
E-cadherin- BM-DCs failed to promote IFN-γCD4+ T
cell generation, due to increased overall cell numbers,
E-cadherin+, but not E-cadherin-, BM-DCs enhanced the
Th1 and Th17 responses. E-cadherin + BM-DCs derive
from inflammatory Gr1+ monocytes and express Gr1 [3].
Blood-derived Gr1+ inflammatory DCs can induce a Th1
response to infection in vivo [19]. Here, CD40-mediated
inflammatory E-cadherin +DCs promoted the Th1 re-
sponse, whereas Th2 responses were decreased when these
Figure 4 The effect of inflammatory E-cadherin + DCs on CD4 helper T cell, CEA-specific CD8+ T cell and CD103 + CD8+ T cell responses
in an orthotopic lung tumour model. (A) The microscopic image of a Lewis cell, an HE-stained image and the established orthotopic lung
tumour model at day 7 (at day 7, 2 tumour-bearing mice were sacrificed, and the tumour tissues were stained with HE). (B) The variations of
orthotopic lung tumour volume (day 28) in response to injection of E-cadherin + DCs, E-cadherin- DCs and PBS (each group, n = 5) and representative
image of the tumours formed. (C) The percentage of CEA tetramer + CD8+ T cells and CD103 + CD8+ T cells, as gated on CD8+ T cells, in the
E-cadherin + DCs, E-cadherin- DCs and PBS groups. The tumour-bearing mice had been injected with E-cadherin + DCs or E-cadherin- DCs
and sacrificed at day 28. Tumour tissues (each group n = 3) were analysed by qPCR and western blotting to assess Th1, Th2, Th17 and
Treg cells. (D) Relative gene expression of T-bet, GATA3, Foxp3 and RORγt by PCR. (E) Relative protein expression of IFN-γ, IL-4, TGF-β
and IL-17 by western blotting. Each experiment was performed in triplicate. An asterisk indicates a significant difference between the two
test groups, as analysed by Student’s t-test (*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001).
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:11 Page 7 of 10DCs were carrying the CEA antigen peptide. As IFNγ
and IL-12 dominate, the enhanced Th1 response can in-
hibit Th2 cell development through a reduction in IL-4
expression [20]. The Th1 response promotes host re-
sponses to tumours because IFN-γ and IL-2 can prime the
CD8+ T cell response, thereby protecting the host by
monitoring against tumour development [21-23]. Never-
theless, the effect of the Th2 response on the tumour is
controversial. In the 1990s, IL-4 was identified as a potentanti-tumour factor [24]. Recently, the Th2 response has
been considered a factor promoting tumour growth that
affects CD8+ T cells. IL-4 was found to stimulate CD8+ T
cells to differentiate into non-lytic CD4−CD8− T cells and
to reduce the susceptibility of human CD8+ T cells to acti-
vate induced cell death [25].
The effect of inflammatory E-cadherin +DCs to the
blance of Th17/Treg is unknown in tumour immune micro-
environment. As is well-known that Treg cells contribute to
Figure 5 Therapeutic efficacy of E-cadherin + DCs on lung
tumour-bearing mice. (A) Changes in the tumour size in
subcutaneous lung tumour-bearing mice. The tumour diameters
(width*length) were measured using callipers every 2–3 days for the
subcutaneous tumour model after E-cadherin + DCs were injected
(each group n = 11). The mean size of the subcutaneous tumours of
the mice that developed tumours in each group after tumour challenge.
Three individual mice per group were analysed. In the E-cadherin + DC
group, tumour volume decreased significantly compared with the
E-cadherin- DC group. In the E-cadherin + DC and E-cadherin- DC
groups, tumour volume increased slower than in the PBS group.
(B) Survival curves of the subcutaneous tumour-bearing mice (each
group n = 11). The E-cadherin + DC groups survived longer than the
E-cadherin- DC groups, and both the E-cadherin +DC and E-cadherin- DC
group survived longer than the PBS group. (C) Survival curves of
the orthotopic lung tumour-bearing mice (each group n = 9). The
E-cadherin + DC group survived longer than the E-cadherin- DC group,
and both the E-cadherin + DC and E-cadherin- DC groups survived
longer than the PBS group. Each experiment was performed in
triplicate. The data were analysed by Student’s t-test (*P < 0.05,
**P < 0.01, ***P < 0.001).
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munity [26,27]. Even though it is protective factors in col-
itis, with suppressive functions through IL-10 and FOXP3
[28]. Inflammatory E-cadherin + DCs from the CD4+
CD45RBhigh T cell model demonstrate a potent ability to
induce T cell-mediated colitis with Th17 responses; the
effect on Treg cells was not significant with E-cadherin-
DCs [3]. However, we found that CD40-mediated E-
cadherin +DCs enriched the Th17 response and signifi-
cantly inhibited the Treg response when the DCs were
carrying the CEA peptide. Treg-mediated suppression is
a crucial component of CD8+ T cell repopulation [29].
Th17 cells are related to IL-17 and mediated by Th17-
stimulated CD8+ T cells in the induction of preventive
and therapeutic antitumour immunity [30]. However,
IL-17 and IL-23 have been found to drive tumour growth
in colorectal cancer with Th17-mediated intestinal inflam-
mation [31]. With Treg cell development impaired by
E-cadherin+ DCs and the increased number of Th17
cells, CEA-specific CD8+ T cell responses are enhanced in
the in vivo lung tumour model. Tumour volume de-
creased, and the survival time of tumour-bearing mice
was prolonged significantly following the injection of
CD40-mediated inflammatory E-cadherin+ DCs compared
with injection of E-cadherin− DCs. These results may be
relevant to the comprehensive effects of Th1 and Th17 on
the proliferation of tumour antigen-specific CD8+ T cell
responses. The promotion of tumour growth by CD4+
helper T cells and CD8+ T cells is subdued with the inter-
vention of CD40-mediated inflammatory E-cadherin +
DCs. In particular, as the CD40 signalling pathway is acti-
vated, the expression of CD40 in the E-cadherin+ DCs is
upregulated, and naive CD4+ and CD8+ T cells are primed
because helper T cells and the generation of CTLs by
cross-priming are mediated by signalling through CD40
on the antigen-presenting cell [32].
Interestingly, the results of transferring CD40-mediated
E-cadherin + DCs into the Lewis lung tumour model sug-
gest that the development of helper T cells in vivo is simi-
lar to that in the in vitro experiments. Furthermore, the
tumour-specific CD8+ T cell responses were significantly
enhanced following the addition of E-cadherin + DCs car-
rying CEA in vivo. Additionally, when E-cadherin + DCs
were cultured with naïve CD8+ T cells, the production of
IFN-γ was greater than when E -cadherin− DCs were used
(Additional file 1: Figure S3). In the Th1 response, CD8
cytotoxic-T cell responses increased, Treg responses
decreased, and the tumour volume was decreased. CD40-
mediated inflammatory E-cadherin + DCs therefore pos-
sess an excellent antitumour ability via enhancement of
the anti-tumour T cell response and suppression of Treg
cell development. Recently, CD103 + CD8+ T cells have
been shown to be effective in inhibiting breast cancer and
glioma progression. These CD103+CD8+ T cells can also
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:11 Page 9 of 10upregulate CD8+ T cell cytotoxic mediators when in
contact with their specific antigen. CD103+CD8+ T cells
also contribute to protecting the human lung against viral
infection by producing IFN-γ and other Th1 cytokines,
such as IL-2. In addition, these cells have an effector or
memory phenotype [33]. In our vivo experiments, we
demonstrated that E-cadherin + DCs are able to enhance
the development and accumulation of CD103+CD8+ T
cells. The ligand for CD103 is E-cadherin; thus, E-
cadherin-expressing DCs are more likely to be recognised
and combined by CD103+CD8+ T cells during antigen
peptide capture, thereby activating these CD8+ T cells.
Conclusions
Taken together, these results strongly suggest that Anti-
CD40-induced inflammatory E-cadherin + DCs promote
T cell responses and antitumour activity in murine Lewis
lung carcinoma. It is unknown why inflammatory E-
cadherin+ DCs accumulate in the presence of CD40 sig-
nalling pathway activation only in innate immunity. A
further understanding of the mechanisms of CD40 sig-
nalling pathway-mediated inflammatory E-cadherin +
DC differentiation in innate immunity and the tumour
microenvironment may provide novel therapeutic strat-
egies and insight into the pathogenesis of NSCLC.
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tured with naive CD8+T cells respectively. Figure S4. Purified agonist
CD40 antibody and established anti-CD40 model. Figure S5. The effect
of inflammatory E-cadherin+ DCs on CEA-specific CD8+ T cell responses
in an orthotopic lung tumour model [34,35].
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